# Radiopharmaceuticals Market Report: Size, Share & Trends 2026–2035

> The Global Radiopharmaceuticals market was worth USD 9,248.6 Mn in 2025 and will reach USD 25,884.6 Mn by 2035 at a 10.84% CAGR, according to Vectomat Insights. North America leads with 40.3% of revenue. Diagnostic radiopharmaceuticals hold a 57.0% share, while Lutetium-177 and Actinium-225 therapeutics grow faster, and Asia Pacific is the fastest-growing region.

- Publisher: Vectomat Insights
- Report code: VMI-1-1-62641
- Published: 2026-10-14
- Canonical URL: https://www.vectomatinsights.com/report/radiopharmaceuticals-market
- Base year 2025: USD 9,248.6 Mn
- Forecast 2035: USD 25,884.6 Mn
- CAGR 2026–2035: 10.84%

## Key insights

- The Global Radiopharmaceuticals market grows from USD 9,248.6 Mn in 2025 to USD 25,884.6 Mn by 2035, a 10.84% CAGR across the 2026–2035 forecast horizon.
- Diagnostic radiopharmaceuticals are the dominant product type at 57.0% of 2025 revenue (USD 5,272.5 Mn), anchored by Technetium-99m, which holds 33.7% of isotope-level value on its own.
- Therapeutic radiopharmaceuticals are the fastest-growing product type, rising from USD 2,991.5 Mn in 2023 to USD 3,976.1 Mn in 2025, a 15.3% two-year CAGR; Fluorine-18 is the fastest-growing isotope at 15.1%.
- Oncology is the dominant application at 46.8% of 2025 revenue (USD 4,327.2 Mn) because PSMA-PET imaging and Lutetium-177 radioligand therapy are both concentrated in prostate and neuroendocrine cancers; neurology grows fastest at a 17.1% two-year CAGR.
- Hospitals capture 53.2% of end-user revenue (USD 4,924.1 Mn) as the only sites licensed and staffed to administer most radioligand therapies, while cancer treatment centers expand fastest at 12.4%.
- North America leads with a 40.3% share (USD 3,727.2 Mn); the U.S. alone reached USD 2,929.2 Mn in 2025 and is forecast at USD 7,193.2 Mn by 2035.
- Asia Pacific is the fastest-growing region, led by South Korea's 13.0% country CAGR and Japan's 11.1%, as both countries add domestic isotope supply and approve radioligand therapies.
- Consolidation is redrawing the competitive map: Curium agreed to acquire Lantheus for up to USD 8.0 Bn in August 2026, and GE HealthCare agreed to buy Sofie Biosciences for USD 945 Mn in October 2026.
- Isotope supply, not demand, sets the ceiling through 2035 — SNMMI warned in June 2025 that dose needs could rise up to sixfold versus 2024 estimates, putting Actinium-225 and Lutetium-177 capacity at a premium.

## Figures

![Radiopharmaceuticals market size — USD 9,248.6 Mn (2025) to USD 25,884.6 Mn (2035), 10.84% CAGR | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-size-vmi.png) — The Global Radiopharmaceuticals market grows from USD 9,248.6 Mn in 2025 to USD 25,884.6 Mn by 2035 at a 10.84% CAGR. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market drivers, restraints, opportunities and challenges | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-droc-vmi.png) — Radioligand label expansion, PET reimbursement and new isotope capacity drive the market, while fragile isotope supply and generic pricing pressure restrain it. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market share by region — North America leads with 40.3% in 2025 | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-regional-share-vmi.png) — North America leads the Global Radiopharmaceuticals market with a 40.3% share in 2025, while Asia Pacific is the fastest-growing region. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market segmentation — Diagnostic 57.0%, Technetium-99m 33.7%, Oncology 46.8% | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-segments-vmi.png) — Diagnostic radiopharmaceuticals, Technetium-99m, oncology and hospitals are the dominant sub-segments in their dimensions in 2025. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market share by product type — Diagnostic 57.0%, Therapeutic 43.0% (2025) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-product-type-share-vmi.png) — Diagnostic radiopharmaceuticals hold 57.0% of 2025 revenue and therapeutic radiopharmaceuticals 43.0%. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market share by end user — Hospitals lead with 53.2% (2025) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-end-user-share-vmi.png) — Hospitals account for 53.2% of 2025 end-user revenue, ahead of diagnostic imaging centers at 23.0%. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals product type mix by region — therapy share highest in North America | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-regional-segments-vmi.png) — North America has the most therapy-heavy mix, with therapeutic agents near half of regional revenue, while Asia Pacific remains more diagnostic-led. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals competitive landscape — supply control vs portfolio scale for 11 companies | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-competitive-landscape-vmi.png) — Novartis and Curium combine integrated isotope supply with multi-product revenue, while Lantheus and GE HealthCare lead on agent scale and buy in isotope supply. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Radiopharmaceuticals market at a glance — USD 9,248.6 Mn (2025) to USD 25,884.6 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-key-numbers-vmi.png) — The Global Radiopharmaceuticals market reaches USD 25,884.6 Mn by 2035, led by North America, diagnostic agents and oncology, with Asia Pacific growing fastest. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![United States radiopharmaceuticals market — USD 2,929.2 Mn (2025) to USD 7,193.2 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-united-states-snapshot-vmi.png) — The United States Radiopharmaceuticals market grows from USD 2,929.2 Mn in 2025 to USD 7,193.2 Mn by 2035 at a 9.4% CAGR. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![Germany radiopharmaceuticals market — USD 680.8 Mn (2025) to USD 1,611.7 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-germany-snapshot-vmi.png) — The Germany Radiopharmaceuticals market grows from USD 680.8 Mn in 2025 to USD 1,611.7 Mn by 2035 at a 9.0% CAGR. Source: Vectomat Insights, Radiopharmaceuticals Market Report.
![South Korea radiopharmaceuticals market — USD 280.9 Mn (2025) to USD 953.5 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/radiopharmaceuticals-market/radiopharmaceuticals-market-south-korea-snapshot-vmi.png) — The South Korea Radiopharmaceuticals market grows from USD 280.9 Mn in 2025 to USD 953.5 Mn by 2035 at a 13.0% CAGR. Source: Vectomat Insights, Radiopharmaceuticals Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 7,547.1 |
| 2024 | 8,354.7 |
| 2025 | 9,248.6 |
| 2026 | 10,251.1 |
| 2027 | 11,362.4 |
| 2028 | 12,594.1 |
| 2029 | 13,959.2 |
| 2030 | 15,472.4 |
| 2031 | 17,149.6 |
| 2032 | 19,008.7 |
| 2033 | 21,069.2 |
| 2034 | 23,353.1 |
| 2035 | 25,884.6 |

## Share by Product Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Diagnostic Radiopharmaceuticals | 57.0% | 5,272.5 |
| Therapeutic Radiopharmaceuticals | 43.0% | 3,976.1 |

## Share by Isotope Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Technetium-99m | 33.7% | 3,116.3 |
| Iodine-131 | 12.3% | 1,138.2 |
| Lutetium-177 | 17.2% | 1,589.9 |
| Gallium-68 | 10.6% | 984.3 |
| Fluorine-18 | 13.5% | 1,245.6 |
| Actinium-225 | 4.8% | 439.6 |
| Yttrium-90 | 4.9% | 453.3 |
| Radium-223 | 3.0% | 281.4 |

## Share by Application (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Oncology | 46.8% | 4,327.2 |
| Cardiology | 20.6% | 1,909.7 |
| Neurology | 16.3% | 1,511.1 |
| Thyroid Disorders | 10.3% | 954.0 |
| Others | 5.9% | 546.6 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Hospitals | 53.2% | 4,924.1 |
| Diagnostic Imaging Centers | 23.0% | 2,128.3 |
| Academic & Research Institutes | 13.0% | 1,205.9 |
| Cancer Treatment Centers | 10.7% | 990.3 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 40.3% | 3,727.2 |
| Europe | 25.9% | 2,395.4 |
| Asia Pacific | 22.7% | 2,099.4 |
| Latin America | 4.9% | 453.2 |
| The Middle East | 3.1% | 286.7 |
| Africa | 3.1% | 286.7 |

## Key companies

- Novartis (Switzerland): Lutetium-177 radioligand therapies (Pluvicto, Lutathera) and the Locametz PSMA imaging kit
- Lantheus (United States): PSMA-PET (Pylarify), cardiac ultrasound and neurology PET imaging agents
- Curium (United States): SPECT and PET agents, Mo-99 and I-131 supply, and generic Lutetium-177 radioligands
- GE HealthCare (United States): SPECT and PET diagnostic agents, Flyrcado cardiac PET and MIM theranostics software
- Bayer (Germany): Radium-223 (Xofigo) and Actinium-225 targeted alpha therapies
- Telix Pharmaceuticals (Australia): Gallium-68 PSMA-PET kits (Illuccix, Gozellix) and a radioligand therapy pipeline
- Cardinal Health (United States): U.S. nuclear pharmacy network (about 130 sites) and PET cyclotron facilities
- Eckert & Ziegler (Germany): Ga-68 generators, Lutetium-177 and Actinium-225 isotope supply
- ITM Isotope Technologies Munich (Germany): Non-carrier-added Lutetium-177 supply and the ITM-11 radioligand candidate
- NorthStar Medical Radioisotopes (United States): Accelerator-produced non-carrier-added Actinium-225 and CDMO services
- Bristol Myers Squibb (United States): Actinium-225 radiopharmaceutical therapies through RayzeBio (RYZ101)
- Siemens Healthineers (Germany): PET tracer manufacturing and distribution through PETNET Solutions
- SHINE Technologies (United States): Non-carrier-added Lutetium-177 (Ilumira) and Mo-99 production
- Jubilant Pharmova (India): SPECT and PET radiopharmaceuticals (Ruby-Fill) and the second-largest U.S. radiopharmacy network
- SK Biopharmaceuticals (South Korea): Actinium-225 radiopharmaceutical therapy candidate SKL35501

## FAQs

### What does the VMI Radiopharmaceuticals report include?

The report covers market size history for 2023–2025 and forecasts to 2035, four segmentation dimensions, a patient-dose Production & Volume analysis, six regional chapters with country snapshots for the U.S., Germany and South Korea, and a full drivers, restraints, opportunities and challenges framework. It also profiles 15 companies across isotope supply, drug development and radiopharmacy distribution, and tracks 2026 deals and approvals, according to Vectomat Insights.

### What is the Radiopharmaceuticals market size and forecast?

Vectomat Insights values the Global Radiopharmaceuticals market at USD 9,248.6 Mn in 2025 and projects USD 25,884.6 Mn by 2035, a CAGR of 10.84% across the forecast period. Revenue rose from about USD 7,547 Mn in 2023, and the fastest increments come from therapeutic doses, Fluorine-18 PET tracers and neurology imaging. North America contributes the largest share at 40.3%, according to Vectomat Insights.

### How is the Radiopharmaceuticals market segmented in this report?

Four dimensions are used. Product type splits diagnostic (57.0%) from therapeutic (43.0%) agents. Isotope type covers eight isotopes, led by Technetium-99m at 33.7%. Application splits oncology (46.8%), cardiology, neurology, thyroid disorders and others. End user covers hospitals (53.2%), diagnostic imaging centers, academic and research institutes, and cancer treatment centers. Each dimension carries 2023–2025 revenue tables and share charts, with the fastest-growing sub-segment flagged, according to Vectomat Insights.

### Which countries are covered in this report?

The report covers 35+ countries across six regions: North America (the U.S., Canada, Mexico), Europe (including Germany, France, the U.K., Italy, Spain and BENELUX), Asia Pacific (including China, Japan, India, South Korea and Australia), Latin America (including Brazil and Argentina), the Middle East (the GCC, Israel, Turkey and Iran) and Africa (including South Africa and Egypt), and Africa and the Middle East analysed separately, according to Vectomat Insights.

### What customization options are available?

Buyers can customize up to 10% of the report scope at no additional cost. Common requests include extra country forecasts, isotope-level pricing and dose analysis, deeper profiles of specific isotope suppliers or radiopharmacy networks, and competitive benchmarking for a named therapy or tracer. Larger custom studies can be scoped separately with the analyst team, and turnaround is typically agreed before purchase, according to Vectomat Insights.

### How can I access or purchase the Radiopharmaceuticals report?

Request a free sample through the Vectomat Insights website to preview the data tables and segmentation depth, then purchase the full PDF online or by emailing sales@vectomatinsights.com. Delivery is by email and through the online download portal. Single-user, multi-user and enterprise licences are available, and the analyst team can answer scope questions before purchase. Updates are available as new approvals and deals land, according to Vectomat Insights.

### What research methodology does VMI use for this report?

VMI combines top-down regional spending analysis with a bottom-up build of patient doses by isotope and product, validated against reported revenue for products such as Pluvicto and Pylarify. Primary interviews with nuclear medicine physicians, radiopharmacy managers and isotope suppliers inform pricing and capacity assumptions.

Cite as: Vectomat Insights (2026). Radiopharmaceuticals Market Report. https://www.vectomatinsights.com/report/radiopharmaceuticals-market